Browse > Article
http://dx.doi.org/10.3857/jkstro.2009.27.3.120

The Preliminary Results of Intensity-Modulated Radiotherapy for Tonsillar Cancer  

Park, Geum-Ju (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine)
Lee, Sang-Wook (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine)
Choi, Eun-Kyung (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine)
Kim, Jong-Hoon (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine)
Song, Si-Yeol (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine)
Youn, Sang-Min (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine)
Park, Sung-Ho (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine)
Park, Dong-Wook (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine)
Ahn, Seung-Do (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine)
Publication Information
Radiation Oncology Journal / v.27, no.3, 2009 , pp. 120-125 More about this Journal
Abstract
Purpose: We wanted to present the preliminary results of intensity-modulated radiotherapy (IMRT) for the treatment of tonsillar cancer. Materials and Methods: We retrospectively analyzed 12 patients who underwent IMRT for tonsillar cancer at Asan Medical Center between November 2002 and February 2007. Seven patients (58%) received definitive treatment, and five (42%) were treated in the postoperative setting. Among the definitively treated patients, 6 patients received cisplatin-based chemotherapy regimens. Simultaneous modulated accelerated radiation therapy (SMART) was used in nine patients. The prescribed dose was 72 Gy at 2.4 Gy/fraction for the definitively treated cases and 61.6 Gy at 2.2 Gy/fraction for the postoperative cases. The median follow-up period was 34 months. Results: All twelve patients completed treatment without interruption, and eleven showed a complete response. One patient had persistent loco-regional disease after treatment. The three-year estimates of loco-regional control, disease-free survival and overall survival were 91.7%, 91.7%, and 100%. The worst acute mucositis was Grade 1 in four patients, Grade 2 in five patients, Grade 3 in two patients and Grade 4 in one patient. Grade 3 xerostomia was observed in six patients. Conclusion: Intensity-modulated radiotherapy was shown to be a safe and effective treatment modality for tonsillar cancer. Further studies with a larger number of patients and a longer follow-up period are needed to evaluate the ultimate tumor control and late toxicity of IMRT for treating tonsillar cancer.
Keywords
Tonsillar cancer; Intensity-modulated radiotherapy; Radiotherapy;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Central Cancer Registry Center. Annual Report of the Central Cancer Registry in Korea, 2002. Seoul; Ministry of Health and Welfare, 2007
2 Chao KS, Ozyigit G, Tran BN, Cengiz M, Dempsey JF, Low DA. Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2003;55:312-321   DOI   PUBMED   ScienceOn
3 Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481   DOI   ScienceOn
4 Wolden SL, Chen WC, Pfister DG, Kraus DH, Berry SL, Zelefsky MJ. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the memorial sloan-kettering experience. Int J Radiat Oncol Biol Phys 2006;64:57-62   DOI   PUBMED   ScienceOn
5 Chao KS. Dose prescription and target delineation for nodal volume. Philadelphia, PA; Lippincott Co, 2003
6 Butler EB, Teh BS, Grant WH 3rd, et al. Smart (simultaneous modulated accelerated radiation therapy) boost:a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys 1999;45:21-32   DOI   PUBMED   ScienceOn
7 Chao KS, Ozyigit G, Blanco AI, et al. Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume. Int J Radiat Oncol Biol Phys 2004;59:43-50   DOI   PUBMED   ScienceOn
8 Chao KS, Majhail N, Huang CJ, et al. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiother Oncol 2001;61:275-280   DOI   ScienceOn
9 American Joint Committee on Cancer. AJCC Cancer Staging Manual. 6th ed. New York; Springer, 2002
10 Eisbruch A, Marsh LH, Dawson LA, et al. Recurrences near base of skull after IMRT for head-and-neck cancer:implications for target delineation in high neck and for parotid gland sparing. Int J Radiat Oncol Biol Phys 2004;59:28-42   DOI   PUBMED   ScienceOn
11 Wu Q, Manning M, Schmidt-Ullrich R, et al. The potential for sparing of parotids and escalation of biologically effective dose with intensity-modulated radiation treatments for head and neck cancers: a treatment design study. Int J Radiat Oncol Biol Phys 2000;46:195-205   DOI   ScienceOn
12 Sanguineti G, Gunn GB, Endres EJ, Chaljub G, Cheruvu P, Parker B. Patterns of locoregional failure after exclusive IMRT for oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2008;72:737-746   DOI   PUBMED   ScienceOn
13 Schoenfeld GO, Amdur RJ, Morris CG, et al. Patterns of failure and toxicity after intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2008;71:377-385   DOI   PUBMED   ScienceOn
14 Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16   DOI   ScienceOn
15 de Arruda FF, Puri DR, Zhung J, et al. Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys 2006;64:363-373   DOI   PUBMED   ScienceOn
16 Park JH, Lee SW, Back GM, et al. Preliminary results of phase I/II study of simultaneous modulated accelerated (SMART) for nasopharyngeal carcinoma. J Korean Soc Ther Radiol Oncol 2006;24:1-10
17 Devita VT, Lawrence TS, Steven A, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology. 8th ed. Philadelpia; Lippincott Williams & Wilkins, 2005:839-844
18 Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-1346   DOI   PUBMED   ScienceOn
19 Chao KS, Deasy JO, Markman J, et al. A prospectiven study of salivary function sparing in patients with head-andneck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys 2001;49:907-916   DOI   ScienceOn
20 Bjordal K, Kaasa S, Mastekaasa A. Quality of life in patients treated for head and neck cancer: a follow-up study 7 to 11 years after radiotherapy. Int J Radiat Oncol Biol Phys 1994;28:847-856   DOI   PUBMED   ScienceOn
21 Puri DR, Chou W, Lee N. Intensity-modulated radiation therapy in head and neck cancers: dosimetric advantages and update of clinical results. Am J Clin Oncol 2005;28:415-423   DOI   ScienceOn
22 Chao KS, Low DA, Perez CA, Purdy JA. Intensity-modulated radiation therapy in head and neck cancers: the Mallinckrodt experience. Int J Cancer 2000;90:92-103   DOI   ScienceOn